Jufang Chi

Dr. Jufang Chi


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2019 in Journal of Molecular and Cellular Cardiology
Verified
Journal Article
Closed access
LMLiping Meng
Liping Meng
HLHui Lin
Hui Lin
JZJie Zhang
Jie Zhang
NLNa Lin
Na Lin
ZSZhenzhu Sun
Zhenzhu Sun
HGHangyuan Guo
Hangyuan Guo

21 June 2019 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
PDF file
HLHui Lin
Hui Lin
JZJie Zhang
Jie Zhang
TNTingjuan Ni
Tingjuan Ni
NLNa Lin
Na Lin
LMLiping Meng
Liping Meng
HGHangyuan Guo
Hangyuan Guo
Doxorubicin (DOX) is considered as the major culprit in chemotherapy‐induced cardiotoxicity. Yellow wine polyphenolic compounds (YWPC), which are full of polyphenols, have beneficial effects on cardiovascular disease. However, their role in DOX‐induced cardiotoxicity is poorly understood. Due to their antioxidant property, we have been suggested that YWPC could prevent DOX‐induced cardiotoxicity. In this study, we found that YWPC treatment (30 mg/kg/day) significantly improved DOX‐induced cardiac hypertrophy and cardiac dysfunction. YWPC alleviated DOX‐induced increase in oxidative stress levels, reduction in endogenous antioxidant enzyme activities and inflammatory response. Besides, administration of YWPC could prevent DOX‐induced mitochondria‐mediated cardiac apoptosis. Mechanistically, we found that YWPC attenuated DOX‐induced reactive oxygen species (ROS) and down‐regulation of transforming growth factor beta 1 (TGF‐β1)/smad3 pathway by promoting nuclear factor (erythroid‐derived 2)‐like 2 (Nrf2) nucleus translocation in cultured H9C2 cardiomyocytes. Additionally, YWPC against DOX‐induced TGF‐β1 up‐regulation were abolished by Nrf2 knockdown. Further studies revealed that YWPC could inhibit DOX‐induced cardiac fibrosis through inhibiting TGF‐β/smad3‐mediated ECM synthesis. Collectively, our results revealed that YWPC might be effective in mitigating DOX‐induced cardiotoxicity by Nrf2‐dependent down‐regulation of the TGF‐β/smad3 pathway.

1 October 2020 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
JZJie Zhang
Jie Zhang
ZSZhenzhu Sun
Zhenzhu Sun
NLNa Lin
Na Lin
WLWenqiang Lu
Wenqiang Lu
XHXingxiao Huang
Xingxiao Huang
JCJufang Chi
Jufang Chi
Doxorubicin (DOX) is well-known for its potent antitumor activity but limited by its multiple and serious adverse effects. A major adverse effect is acute cardiotoxicity; yet, its mechanism has not been elucidated. Fucoidan is a multifunctional and nontoxic polysaccharide that is widely studied because of its favorable biological activities and safety. Hence, we proposed that fucoidan may play a protective role in DOX-induced acute cardiotoxicity without causing additional side effects. Sprague-Dawley rats were injected intraperitoneally with a single high dose of DOX to induce acute cardiac injury. Fucoidan was administered orally before DOX injection and AG490, a JAK2 inhibitor, was applied to verify the participation of the JAK2/STAT3 pathway. In vitro, H9C2 cells were treated with the same drugs at different concentrations and intervention times. in vivo and in vitro results demonstrated that DOX administration induced myocardial damage accompanied by acceleratory apoptosis and deficient autophagy in heart tissues or cells, which could be significantly improved by fucoidan supplement. AG490 partly abolished the cardioprotective effects of fucoidan, suggesting the involvement of JAK2 signaling. Additionally, western blotting revealed DOX-induced JAK2/STAT3 pathway activation, which was enhanced by fucoidan and weaken by AG490. Hence, fucoidan exerted a favorable effect on DOX-induced cardiotoxicity by enhancing autophagy and suppressing apoptosis in a JAK2/STAT3-dependent manner, which may provide a promising and novel therapeutic strategy against negative chemotherapy-induced effects.

1 October 2018 in International Journal of Cardiology
Verified
Journal Article
Closed access
HLHui Lin
Hui Lin
TNTingjuan Ni
Tingjuan Ni
JZJie Zhang
Jie Zhang
LMLiping Meng
Liping Meng
FGFeidan Gao
Feidan Gao
HGHangyuan Guo
Hangyuan Guo

1 July 2017 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
HLHui Lin
Hui Lin
SPSunlei Pan
Sunlei Pan
LMLiping Meng
Liping Meng
CZChangzuan Zhou
Changzuan Zhou
CJChengjian Jiang
Chengjian Jiang
HGHangyuan Guo
Hangyuan Guo

23 May 2025 in npj Biofilms and Microbiomes
Verified
Journal Article
Open access
PDF file
HLHui Lin
Hui Lin
XSXian Shao
Xian Shao
HGHaodi Gu
Haodi Gu
XYXinrou Yu
Xinrou Yu
LHLingyan He
Lingyan He
LJLian Jiangfang
Lian Jiangfang
Doxorubicin (DOX) is a key chemotherapeutic agent but is also a leading cause of DOX-induced cardiotoxicity (DIC), limiting its clinical use. Akkermansia muciniphila (A. muciniphila), known for its benefits as a probiotic in treating metabolic syndrome, has uncertain effects in the context of DIC. Here, 16S rRNA sequencing of fecal samples from anthracycline-treated patients and DIC mice revealed marked depletion of A. muciniphila. Cardiac transcriptomics, supported by in vitro experiments, showed that A. muciniphila colonization improved mitochondrial function and alleviated DIC by activating the PPARα/PGC1α signaling pathway in both normal and antibiotic-treated C57BL/6 mice. Further analysis uncovered a restructured microbiome–metabolome network following A. muciniphila administration, which contributed to DIC protection. Notably, A. muciniphila supplementation increased serum levels of the tryptophan metabolite indole-3-propionic acid (IPA), which binds to the cardiac aryl hydrocarbon receptor (AhR), leading to the activation of the PPARα/PGC1α signaling pathway. In conclusion, our study sheds light on the potential of A. muciniphila as a probiotic in mitigating DIC.